191 related articles for article (PubMed ID: 18066009)
1. Pfizer dumps Exubera.
Mack GS
Nat Biotechnol; 2007 Dec; 25(12):1331-2. PubMed ID: 18066009
[No Abstract] [Full Text] [Related]
2. Inhaled insulin products puff along.
Powell K
Nat Biotechnol; 2004 Oct; 22(10):1195-6. PubMed ID: 15470441
[No Abstract] [Full Text] [Related]
3. The market in diabetes.
Hauber A; Gale EA
Diabetologia; 2006 Feb; 49(2):247-52. PubMed ID: 16416145
[No Abstract] [Full Text] [Related]
4. First inhalable insulin approved.
Katsnelson A
Nat Biotechnol; 2006 Apr; 24(4):369-70. PubMed ID: 16601705
[No Abstract] [Full Text] [Related]
5. Medical advances. For many diabetics, development of oral insulin--whether via an inhaler or a capsule--could mean the end of daily needlesticks and the beginning of a simpler treatment regimen.
Becker C
Mod Healthc; 2003 Sep; 33(36):32-4. PubMed ID: 14520835
[No Abstract] [Full Text] [Related]
6. What went wrong? A retrospective on Exubera.
Baran MK; Godoy AT
Adv Nurse Pract; 2008 Nov; 16(11):53-4, 77. PubMed ID: 19999057
[No Abstract] [Full Text] [Related]
7. Inhaled insulin--does it become reality?
Siekmeier R; Scheuch G
J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():81-113. PubMed ID: 19218634
[TBL] [Abstract][Full Text] [Related]
8. Dying of diabetes.
Gale EA
Lancet; 2006 Nov; 368(9548):1626-8. PubMed ID: 17098062
[No Abstract] [Full Text] [Related]
9. Inhaled insulin: gone with the wind?
Mathieu C; Gale EA
Diabetologia; 2008 Jan; 51(1):1-5. PubMed ID: 18026925
[No Abstract] [Full Text] [Related]
10. Identifying factors that affect patients' willingness to pay for inhaled insulin.
Pinto SL; Holiday-Goodman M; Black CD; Lesch D
Res Social Adm Pharm; 2009 Sep; 5(3):253-61. PubMed ID: 19733826
[TBL] [Abstract][Full Text] [Related]
11. Exit Exubera. Inhalable insulin is withdrawn due to weak sales.
Keegan A
Diabetes Forecast; 2007 Dec; 60(13):19. PubMed ID: 18217270
[No Abstract] [Full Text] [Related]
12. Drug delivery takes a deep breath.
Service RF
Science; 1997 Aug; 277(5330):1199-200. PubMed ID: 9297235
[No Abstract] [Full Text] [Related]
13. Diabetes research investment in the European Union.
Halban PA; Ferrannini E; Nerup J
Nat Med; 2006 Jan; 12(1):70-2. PubMed ID: 16397573
[No Abstract] [Full Text] [Related]
14. [Real-world studies for answering real-world questions].
Freemantle N
Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S77-81. PubMed ID: 15988673
[No Abstract] [Full Text] [Related]
15. [The changeover to insulin U100. Clinical and pharmacoeconomic suggestions].
Costa B
Med Clin (Barc); 1996 Apr; 106(13):495-7. PubMed ID: 8992131
[No Abstract] [Full Text] [Related]
16. Drug companies accused of stalling tailored therapies.
Sinha G
Nat Med; 2006 Sep; 12(9):983. PubMed ID: 16960561
[No Abstract] [Full Text] [Related]
17. Diabetes costs rise, but so does adherence.
Manag Care; 2005 Apr; 14(4):54. PubMed ID: 15898213
[No Abstract] [Full Text] [Related]
18. Drugmakers seek gold in doc IT. What Pfizer, Merck see as needed services, critics tie to drug marketing.
Romano M
Mod Healthc; 2001 Oct; 31(44):6-7, 14. PubMed ID: 11715738
[No Abstract] [Full Text] [Related]
19. What price education?
Nat Rev Drug Discov; 2004 Oct; 3(10):815. PubMed ID: 15497244
[No Abstract] [Full Text] [Related]
20. Inhaled insulin no longer marketed: discontinuation. Welcome news.
Prescrire Int; 2008 Aug; 17(96):139. PubMed ID: 19480094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
